Finland - Fins - Fimea (Suomen lääkevirasto)

nordic drugs ab - aluminium hydroxide gel, calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo

Finland - Fins - Fimea (Suomen lääkevirasto)

reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio, annospussi - algiinihappo

Finland - Fins - Fimea (Suomen lääkevirasto)

reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo

Europese Unie - Fins - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Fins - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Europese Unie - Fins - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Finland - Fins - Fimea (Suomen lääkevirasto)

mylan ab - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi

Finland - Fins - Fimea (Suomen lääkevirasto)

sandoz a/s - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi

Finland - Fins - Fimea (Suomen lääkevirasto)

oy verman ab - cetirizine dihydrochloride - tabletti, kalvopäällysteinen - 10 mg - setiritsiini

Finland - Fins - Fimea (Suomen lääkevirasto)

orion corporation - ibuprofen - tabletti, kalvopäällysteinen - 400 mg - ibuprofeeni